Three cases of anti-TNF induced myositis and literature review

Zengin, Orhan; Onder, Mustafa Erkut; Alkan, Samet; Kimyon, Gezmiş; Hüseynova, Nergis; Demir, Zeynep Hanım; Kisacik, Bunyamin; Onat, Ahmet Mesut

doi:10.1016/j.rbre.2016.05.003

Cited by 13 publications

(8 citation statements)

References 22 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several authors showed an efficacy of TNF-α inhibitor, cases of exacerbation and even fatalities have also been described. 3 , 4 , 5 , 6 Moreover, induction of dermatomyositis by TNF-α inhibitor has been reported as well, with most inductions in rheumatoid arthritis patients. 7 The most common TNF-α inhibitor associated with dermatomyositis is etanercept, followed by adalimumab and infliximab.…”

Section: Discussionmentioning

confidence: 99%

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

et al. 2020

View full text Add to dashboard Buy / Rent full text

Section: Discussionmentioning

confidence: 99%

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

et al. 2020

View full text Add to dashboard Buy / Rent full text

“…5,6 TNF-alpha inhibitors are widely used biological agents for autoimmune diseases, such as rheumatoid arthritis and ulcerative colitis, but they occasionally induce or exacerbate autoimmune neurological diseases. [1][2][3][4]7 Recent studies have shown that anti-ARS antibodies were detected in some patients with new-onset inflammatory myopathies during treatment of TNF-alpha inhibitors. 3,4 However, it is not clarified whether TNF-alpha inhibitors induce inflammatory myopathies with other myositis-specific antibodies.…”

Section: Discussionmentioning

confidence: 99%

“…[1][2][3][4]7 Recent studies have shown that anti-ARS antibodies were detected in some patients with new-onset inflammatory myopathies during treatment of TNF-alpha inhibitors. 3,4 However, it is not clarified whether TNF-alpha inhibitors induce inflammatory myopathies with other myositis-specific antibodies. To our knowledge, our patient is the first case of anti-Mi-2 antibody-positive inflammatory myopathy during treatment of a TNF-alpha inhibitor.…”

Section: Discussionmentioning

confidence: 99%

“…Tumor necrosis factor (TNF)-alpha inhibitors occasionally induce autoimmune neurological diseases, such as central demyelination, chronic inflammatory demyelinating polyneuropathy, and inflammatory myopathies. [1][2][3][4] New-onset inflammatory myopathies with anti-aminoacyl-tRNA synthetases (ARS) antibodies during anti-TNF-alpha therapies have been reported, 3,4 but it is unclear whether TNF-alpha inhibitors induce inflammatory myopathies with other myositis-specific antibodies. We herein present a case of anti-Mi-2 antibodypositive inflammatory myopathy during treatment with golimumab.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Anti‐Mi‐2 antibody‐positive inflammatory myopathy during treatment with golimumab

Hirunagi

Goto

Mano

2018

Neurology & Clinical Neurosc

View full text Add to dashboard Buy / Rent full text

A 56‐year‐old woman, who was treated with golimumab for rheumatoid arthritis, presented with myalgia and rash. She had proximal limbs weakness, and erythematous papules were evident on her hands and face. Her serum creatine kinase levels were elevated, and anti‐Mi‐2 antibody was detected. Magnetic resonance imaging of muscles revealed inflammatory lesions in muscles and soft tissues. She was diagnosed with inflammatory myopathy. A drug‐induced mechanism was suspected; therefore, we stopped treating her with golimumab and instead treated her with prednisolone. Subsequently, her symptoms gradually improved. This case suggests that tumor necrosis factor‐alpha inhibitors may induce anti‐Mi‐2 antibody‐positive inflammatory myopathies.

show abstract

“…[ 57 ] Rare cases of myositis developing after the use of TNF alpha inhibitor etanercept have recently been described. [ 58 ] Infliximab use in refractory myositis has mixed results in small series and case reports. Alemtuzumab (depletes both B and T cells through interfering with the T cell signaling pathways by recognition of CD52 on B and T lymphocytes and natural killer cells), abatacept (upregulates costimulatory molecules, CD28, and CTLA-4), sifalimumab (interferon (IFN) alpha/beta immune response) and tocilizumab (interleukin IL -6 antagonist) are being studied as therapeutic targets in refractory myositis.…”

Section: T Reatment Of a Utoimmune mentioning

confidence: 99%

What is new in idiopathic inflammatory myopathies: Mechanisms and therapies

Khadilkar

Dhamne²

2020

Ann Indian Acad Neurol

View full text Add to dashboard Buy / Rent full text

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of disorders that cause muscle weakness and also have extramuscular manifestations involving various organ systems; namely the lung, skin, heart, and joints. Previously classified broadly as dermatomyositis (DM) and polymyositis now the spectrum of the disease has evolved into more clinical subtypes. There are now five clinicoserological subtypes recognized worldwide DM, antisynthetase syndrome (AS), overlap myositis (OM), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis. Each of these subtypes has a unique phenotype and specific antibodies associated. With the evolving treatment options from the use of immunosuppressive medications to the use of targeted therapy with biologic agents, and further understanding of the pathogenesis of inflammatory myositis, we may have more effective treatment options. We discuss in this review, various myositis-associated antibodies associated with each clinicoserological subtype of IIM and their role. We also describe the evolving therapies and the evidence for the newer biologic therapies in the treatment of IIMs.

show abstract

Three cases of anti-TNF induced myositis and literature review

Cited by 13 publications

References 22 publications

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

Dermatomyositis–lupuslike syndrome overlap under treatment with etanercept for rheumatoid arthritis

Anti‐Mi‐2 antibody‐positive inflammatory myopathy during treatment with golimumab

What is new in idiopathic inflammatory myopathies: Mechanisms and therapies

Contact Info

Product

Resources

About